Evidence map›Paper›PMID 29562983›Full record

Trial reportThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease2018

Predictors of isoniazid preventive therapy completion among adults newly diagnosed with HIV in rural Malawi.

K M Little, M Khundi, G L Barnes, L G Ngwira, A Nkhoma, S Makombe, E L Corbett, R E Chaisson, D W Dowdy

Open access · greenAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 3 pooled it
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 3 syntheses or guidelines pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

K M LittleEpidemiology Department, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
M KhundiMalawi Liverpool Wellcome Trust, Blantyre, Malawi.
G L BarnesDepartment of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
L G NgwiraMalawi Liverpool Wellcome Trust, Blantyre, Malawi.
A NkhomaMalawi Liverpool Wellcome Trust, Blantyre, Malawi.
S MakombeMinistry of Health, Malawi, Lilongwe, Malawi.
E L CorbettMalawi Liverpool Wellcome Trust, Blantyre, Malawi, Department of Clinical Research, London School of Hygiene & Tropical Medicine, London, UK.
R E ChaissonDepartment of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
D W DowdyEpidemiology Department, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Johns Hopkins University · USMalawi-Liverpool-Wellcome Trust Clinical Research Programme · MWMinistry of Health · MWUniversity of Liverpool · GB

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
Impact of a New Molecular TB Test on TB/HIV Outcomes among HIV-Infected MalawiansR01AI093316 · NIAID · JOHNS HOPKINS UNIVERSITY · PI CHAISSON, RICHARD E. · 2011 to 2015
$2.8M
NIAID NIH HHS P30 AI094189NIAID NIH HHS R01 AI093316
6 · The paper itself

Abstract

settingTo reduce the risk of tuberculosis (TB) among individuals with human immunodeficiency virus (HIV) infection, the World Health Organization recommends at least 6 months of isoniazid preventive therapy (IPT). Completion of IPT remains a major challenge in resource-limited settings.

objectiveTo evaluate predictors of IPT completion in individuals newly diagnosed with HIV.

designPredictors of IPT completion among adults newly diagnosed with HIV in rural Malawi were evaluated using a multilevel logistic regression model.

resultsOf 974 participants who screened negative for active TB and were started on IPT, 732 (75%) completed treatment. Only one IPT-eligible individual refused treatment. Participants who were aged <25 years (compared with those aged 45 years, adjusted OR [aOR] 0.33, 95%CI 0.18-0.60) and male (compared to non-pregnant females, aOR 0.57, 95%CI 0.37-0.88) had lower odds of IPT completion.

conclusionIPT provision at the time of initial HIV diagnosis was highly acceptable in rural Malawi; three quarters of those who initiated IPT successfully completed therapy. We observed lower odds of completion among males and among female participants aged <25 years. Additional efforts may be needed to ensure IPT completion among males and young females who have recently been diagnosed with HIV.

Indexed as

Drug MonitoringAdolescentAdultAntitubercular AgentsFemaleHIV InfectionsHumansIsoniazidKaplan-Meier EstimateLogistic ModelsMalawiMaleMiddle AgedPregnancyPregnancy RateRisk FactorsAntitubercular AgentsIsoniazid

Identifiers

PMID29562983
PMCPMC6417104
OpenAlexW2793576616

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.